MBQ Pharma announces the First-in-Human Dose for Advanced Breast Cancer
MBQ Pharma announces the First-in-Human Dose for Advanced Breast Cancer with the dual targeted Rac/Cdc42 inhibitor: MBQ-167 SAN JUAN, PUERTO RICO / ACCESSWIRE / December 20, 2023 / MBQ Pharma Inc., a pioneering clinical-stage biopharmaceutical company dedicated to advancing innovative treatments [.mas.]